David Cole to Mice, Inbred C57BL
This is a "connection" page, showing publications David Cole has written about Mice, Inbred C57BL.
Connection Strength
0.939
-
Effect of administration timing of postchemotherapy granulocyte colony-stimulating factor on host-immune cell recovery and CD8+ T-cell response. J Immunotoxicol. 2016 11; 13(6):784-792.
Score: 0.085
-
Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells. Cancer Immunol Immunother. 2015 May; 64(5):539-49.
Score: 0.077
-
Kinetics of rebounding of lymphoid and myeloid cells in mouse peripheral blood, spleen and bone marrow after treatment with cyclophosphamide. Cell Immunol. 2012 Mar-Apr; 276(1-2):67-74.
Score: 0.063
-
Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host. J Am Coll Surg. 2012 Apr; 214(4):700-7; discussion 707-8.
Score: 0.063
-
Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. J Immunol. 2010 Feb 15; 184(4):1737-47.
Score: 0.054
-
Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo. Cell Immunol. 2010; 261(2):134-43.
Score: 0.054
-
The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into na?ve recipient mice. Vaccine. 2009 Jan 22; 27(4):549-57.
Score: 0.050
-
Loss of T cell-mediated antitumor immunity after construct-specific downregulation of retrovirally encoded T-cell receptor expression in vivo. Cancer Gene Ther. 2009 Feb; 16(2):171-83.
Score: 0.049
-
Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother. 2007 Jan; 30(1):40-53.
Score: 0.044
-
The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine. 2006 Jun 12; 24(24):5119-32.
Score: 0.042
-
Bystander effect contributes to the antitumor efficacy of CaSm antisense gene therapy in a preclinical model of advanced pancreatic cancer. Mol Ther. 2006 Feb; 13(2):357-65.
Score: 0.040
-
Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity. J Immunol. 2003 Feb 01; 170(3):1209-17.
Score: 0.033
-
Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination. Clin Cancer Res. 1999 May; 5(5):1173-82.
Score: 0.026
-
Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells. Cancer Res. 2018 06 01; 78(11):3067-3074.
Score: 0.024
-
Characterization of a sustained-release delivery system for combined cytokine/peptide vaccination using a poly-N-acetyl glucosamine-based polymer matrix. Clin Cancer Res. 1997 Jun; 3(6):867-73.
Score: 0.023
-
Lack of p53 Augments Antitumor Functions in Cytolytic T Cells. Cancer Res. 2016 09 15; 76(18):5229-5240.
Score: 0.021
-
IL-2Ra mediates temporal regulation of IL-2 signaling and enhances immunotherapy. Sci Transl Med. 2015 Oct 28; 7(311):311ra170.
Score: 0.020
-
Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Ra Dependent. Cancer Immunol Res. 2015 Dec; 3(12):1364-74.
Score: 0.020
-
IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells. Cancer Gene Ther. 2015 Jul; 22(7):360-7.
Score: 0.020
-
The inducible costimulator augments Tc17 cell responses to self and tumor tissue. J Immunol. 2015 Feb 15; 194(4):1737-47.
Score: 0.019
-
G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses. J Hematol Oncol. 2013 Oct 01; 6:75.
Score: 0.017
-
Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr; 20(4):222-8.
Score: 0.017
-
A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice. J Immunol. 2012 Aug 15; 189(4):1627-38.
Score: 0.016
-
CD8(+) T cells sabotage their own memory potential through IFN-?-dependent modification of the IL-12/IL-15 receptor a axis on dendritic cells. J Immunol. 2012 Apr 15; 188(8):3639-47.
Score: 0.016
-
Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer. J Surg Res. 2012 Aug; 176(2):359-66.
Score: 0.015
-
Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine. J Immunol. 2004 May 01; 172(9):5159-67.
Score: 0.009
-
Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2). Vaccine. 2003 Jun 02; 21(19-20):2318-28.
Score: 0.009
-
Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response. J Immunother. 2001 Sep-Oct; 24(5):420-9.
Score: 0.008
-
Identification of a T-cell receptor from a therapeutic murine T-cell clone. J Immunother. 1997 Jul; 20(4):247-55.
Score: 0.006